Lifestyle imagery of two women wearing sunglasses overlooking a lake with mountains in the background.

How to get LEROCHOL

Available through

Follow these steps to ensure your cash-paying patients get LEROCHOL for $199 through the Cash-Pay Program:*

Enter prescription in EMR and select HealthDyne Pharmacy, the licensed pharmacy provider, for home-delivery fulfillment

HealthDyne Pharmacy
NPI: 1093974982 |
NCPDP eScribe: 1035371

Instruct patient to expect a text from 833-772-4142, which is HealthDyne reaching out with instructions to register on the patient portal, where they will:

Create an account
Provide prescription details, including their known allergies
Submit a payment method

REMIND YOUR PATIENT TO COMPLETE ALL NECESSARY INFORMATION ON THE HEALTHDYNE PORTAL TO AVOID ANY DELAYS

*LEROCHOL prescriptions filled by HealthDyne Pharmacy, the licensed pharmacy provider. Terms and conditions apply. See below.

If your patient prefers to submit through their insurance, prescription must still be submitted through HealthDyne Pharmacy for fulfillment. Please note, some insurance companies may not cover at this time.

Terms and Conditions for the Cash-Pay Program

The LIB Therapeutics direct-to-patient program (the "Program") is available to patients at least 18 years old who have been prescribed LEROCHOL by their physician and who pay out-of-pocket with cash or credit card for LEROCHOL. By participating in this Program, you agree to these terms and conditions.

See full terms and conditions for the Cash-Pay ProgramClose full terms and conditions for the Cash-Pay Program

You will not use insurance to pay for LEROCHOL by submitting any claim for reimbursement to insurance. This includes Medicare Part D, a Medicare Advantage prescription drug plan, Medicaid, and any other federal or commercial insurance policy. You will not count any out-of-pocket costs toward your insurance deductible or true out-of-pocket costs under a Medicare Part D Plan. You will purchase all of your LEROCHOL prescriptions during the year using this Program. The cash price for LEROCHOL is $199 for a one-month supply. It is possible that the amount that you pay for LEROCHOL under this Program could be more than what you would pay if you used insurance.

LIB Therapeutics has partnered with HealthDyne, LLC, a licensed pharmacy, to fill and ship your prescription for LEROCHOL to you. Your physician will need to submit a prescription for LEROCHOL to HealthDyne. Your purchase of LEROCHOL will be subject to HealthDyne's terms and conditions of fulfillment. You should contact HealthDyne about any issues with your product fulfillment.

LEROCHOL is only available to residents of the United States. You are not under any obligation to continue purchasing LEROCHOL. If you have any questions about LEROCHOL, you should contact your prescribing physician. LIB Therapeutics reserves the right to modify or discontinue the Program for any reason at any time without prior notice. These terms are governed by the laws of Ohio. Any dispute arising out of or relating to these terms, the Program, or your purchase of LEROCHOL through the Program, will be governed by the dispute resolution provisions in Section 16 of our Website Terms of Use.

View efficacy across a broad patient range Access LEROCHOL resources

*LEROCHOL prescriptions filled by HealthDyne Pharmacy, the licensed pharmacy provider. Terms and conditions apply. See below.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia in adults (including heterozygous familial hypercholesterolemia [HeFH]) ≥2% of patients treated with LEROCHOL^® (lerodalcibep-liga) and occurring more frequently than with placebo were nasopharyngitis (15% and 14% versus placebo), local injection site reactions (12% and 5% versus placebo) and peripheral edema (2% and <1% versus placebo).

The most commonly occurring adverse reactions in clinical trials in HeFH (≥2% of patients treated with LEROCHOL and occurring more frequently than with placebo) were injection site reactions (18% and 3% versus placebo), nasopharyngitis (13% and 9% versus placebo), diarrhea (3% and 1% versus placebo), nausea (2% and 0% versus placebo) and peripheral edema (2% and <1% versus placebo).

The most frequent adverse reaction leading to treatment discontinuation in trials in primary hypercholesterolemia in adults was injection site reactions, with a higher frequency in the LEROCHOL-treated group compared to placebo-treated patients (1% versus 0%).

Immunogenicity

LEROCHOL is a recombinant fusion protein. As with all therapeutic proteins, there is potential for immunogenicity with LEROCHOL.

INDICATIONS

LEROCHOL^® (lerodalcibep-liga) is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

Cardiovascular outcomes trials have demonstrated that reducing LDL‑C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

INDICATIONS